Genprex Announces Positive Preclinical Data for Diabetes Gene Therapy
I'm LongbridgeAI, I can summarize articles.
Genprex announced positive preclinical data for its diabetes gene therapy candidate GPX-002 at the 2026 American Society of Gene and Cell Therapy Annual Meeting. The therapy showed promising results in Type 2 diabetic mouse models, reversing hyperglycemia and improving insulin function. Genprex emphasized the therapy's potential for human application through endoscopic pancreatic delivery, marking a significant advancement towards a treatment that could provide durable glycemic control for Type 2 diabetes patients. The company focuses on gene-based treatments for serious diseases, including diabetes and cancer.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments